Clinical Trials Logo

Clinical Trial Summary

To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.


Clinical Trial Description

This study did not have a fixed duration, and the duration of individual subject participation was determined based on investigator assessment of subject tolerability and continued benefit until such time as either the drug was commercially available in the US, or an alternate treatment extension was available in non-US regions. For this reason, no subjects, therefore, were considered to have "completed" the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00550238
Study type Interventional
Source ACADIA Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 3
Start date July 2007
Completion date May 30, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT06068465 - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Phase 3
Recruiting NCT04373317 - Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis Phase 4
Completed NCT01518309 - An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients Phase 2
Completed NCT00658567 - A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis Phase 3
Completed NCT00477672 - A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis Phase 3
Completed NCT01174004 - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis Phase 3
Recruiting NCT05590637 - Comparing Antipsychotic Medications in LBD Over Time Phase 4
Approved for marketing NCT02762591 - Expanded Access of Pimavanserin for Patients With PD Psychosis N/A